Clinical Trial: A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT06838273) titled 'A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer' on Feb. 16.

Brief Summary: This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with osimertinib versus osimertinib as first-Line treatment in patients with EGFR-mutated locally advanced or metastatic Non-small Cell Lung Cancer.

Study Start Date: March, 2025

Study Type: INTERVENTIONAL

Condition: Non-small Cell Lung Cancer

Intervention: DRUG: BL-B01D1

Admini...